不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
MG4101（一种同种异体 NK 细胞）治疗复发/难治性急性髓系白血病患者：一项先导研究
英文原题：MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
查看英文原题
MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们评估异体、体外扩增 NK 细胞 MG4101 治疗难治或复发性 AML 患者的安全性和疗效，并分析免疫学特征与临床应答的关系。2018 年 4 月至 2020 年 2 月期间，共有 11 例患者（男:女 = 5:6）接受 MG4101 治疗。在 8 例可评估患者中，2 例（25.0%）部分缓解，2 例（25.0%）疾病稳定。总生存期中位数为 3.4 个月（95% 置信区间 [CI] 2.5–4.3 个月）；按异基因造血干细胞移植（HSCT）删失的缓解持续时间中位数为 2.9 个月（95% CI 1.5–4.4 个月）。2 例患者在 MG4101 治疗后接受 HSCT。除 1 例 3 级输注相关反应外，未观察到严重不良事件。应答者激活性 KIR 总数呈较高趋势。NKRL 和 KIR 分析凸显免疫学机制在治疗髓系肿瘤中的重要性。
展开英文摘要原文
We evaluated the safety and efficacy of allogeneic, ex-vivo expanded, NK cells, MG4101, in patients with refractory or relapsed AML. The relationship between immunological characteristics and clinical responses was analyzed. Between April 2018 and February 2020, 11 patients (male:female = 5:6) were treated with MG4101. Of eight evaluable patients, two (25. 0%) showed partial response and two (25. 0%) showed stable disease. The median overall survival was 3. 4 months (95% confidence interval [95% CI], 2.
5-4. 3 months), and the allogeneic hematopoietic stem cell transplantation (HSCT) censored duration of response was 2. 9 months (95% CI, 1. 5-4. 4 months). Two patients underwent HSCT after MG4101 treatment. Except for one grade 3 infusion-related reaction, no serious adverse events were observed. The sum of activating KIRs in responders tended to be higher than that in non-responders. Analyses of NKRL and KIR highlighted the importance of immunological mechanisms in treating myeloid neoplasms.
论文信息
- 作者
- Kim SA、Jung M、Kim H、Byun JM、Hong J、Shin DY、Kim I、Yoon SS
- 第一作者单位
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.South Korea
- 通讯作者单位
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.South Korea
- 期刊
- Leukemia & lymphoma2025 Feb
- 原文标识
- PubMed 39435506 · DOI 10.1080/10428194.2024.2414903